(Q45046442)

English

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

scientific article published on 26 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. (English)

1 reference

Europe PubMed Central

8 December 2017

0 references

phase III clinical trial

0 references

25

object named as

Merlin L Robb

1 reference

Europe PubMed Central

8 December 2017

24

object named as

Nelson L Michael

1 reference

Europe PubMed Central

8 December 2017

27

object named as

Jerome H Kim

1 reference

Europe PubMed Central

8 December 2017

Supachai Rerks-Ngarm

1

object named as

Supachai Rerks-Ngarm

1 reference

Europe PubMed Central

8 December 2017

Peter B Gilbert

26

object named as

Peter B Gilbert

1 reference

Europe PubMed Central

8 December 2017

Rapee Trichavaroj

9

object named as

Rapee Trichavaroj

1 reference

Europe PubMed Central

8 December 2017

21

object named as

Viseth Ngauy

1 reference

Europe PubMed Central

8 December 2017

Sorachai Nitayaphan

20

object named as

Sorachai Nitayaphan

1 reference

Europe PubMed Central

8 December 2017

Sanjay Gurunathan

16

object named as

Sanjay Gurunathan

1 reference

Europe PubMed Central

8 December 2017

Charla A Andrews

12

object named as

Charla Andrews

1 reference

Europe PubMed Central

8 December 2017

4

object named as

Nakorn Premsri

1 reference

Europe PubMed Central

8 December 2017

Prayura Kunasol

23

object named as

Prayura Kunasol

1 reference

Europe PubMed Central

8 December 2017

James Tartaglia

17

object named as

Jim Tartaglia

1 reference

Europe PubMed Central

8 December 2017

Chirapa Eamsila

19

object named as

Chirapa Eamsila

1 reference

Europe PubMed Central

8 December 2017

Chawetsan Namwat

5

object named as

Chawetsan Namwat

1 reference

Europe PubMed Central

8 December 2017

Chureeratana Bowonwatanuwong

6

object named as

Chureeratana Bowonwatanuwong

1 reference

Europe PubMed Central

8 December 2017

author name string

Robert M Paris

2

1 reference

Europe PubMed Central

8 December 2017

Supamit Chunsutthiwat

3

1 reference

Europe PubMed Central

8 December 2017

Shuying S Li

7

1 reference

Europe PubMed Central

8 December 2017

Jaranit Kaewkungkal

8

1 reference

Europe PubMed Central

8 December 2017

Nampueng Churikanont

10

1 reference

Europe PubMed Central

8 December 2017

Mark S de Souza

11

1 reference

Europe PubMed Central

8 December 2017

Donald Francis

13

1 reference

Europe PubMed Central

8 December 2017

Elizabeth Adams

14

1 reference

Europe PubMed Central

8 December 2017

Jorge Flores

15

1 reference

Europe PubMed Central

8 December 2017

Robert J O'Connell

18

1 reference

Europe PubMed Central

8 December 2017

Prasert Thongcharoen

22

1 reference

Europe PubMed Central

8 December 2017

language of work or name

0 references

publication date

26 July 2012

1 reference

Europe PubMed Central

8 December 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

Journal of Infectious Diseases

1 reference

Europe PubMed Central

8 December 2017

207

1 reference

Europe PubMed Central

8 December 2017

1195-1205

1 reference

Europe PubMed Central

8 December 2017

8

1 reference

Europe PubMed Central

8 December 2017

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Vaccines: correlates of vaccine-induced immunity

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

The role of antibodies in HIV vaccines

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

How innate immune mechanisms contribute to antibody-enhanced viral infections

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Use of predictive markers of HIV disease progression in vaccine trials

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Recent observations on HIV type-1 infection in the genital tract of men and women

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS478

21 January 2018

Identifiers

10.1093/INFDIS/JIS478

1 reference

Europe PubMed Central

8 December 2017

1 reference

Europe PubMed Central

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45046442&oldid=2034574189"